This clinical trial is focused on studying a liver condition known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), which is also referred to as Nonalcoholic Steatohepatitis (NASH) with fibrosis. This condition involves the buildup of fat in the liver, leading to inflammation and scarring, which can affect liver function. The study will evaluate a treatment called Pegozafermin, which is administered as a solution for injection. Pegozafermin is being compared to a placebo to assess its effectiveness and safety in treating this liver condition.

The purpose of the study is to determine how well Pegozafermin works in improving liver health and reducing the risk of further liver damage. Participants in the study will receive either Pegozafermin or a placebo through a pre-filled syringe, which is injected under the skin. The study will last for a period of up to 36 months, with key assessments taking place at 52 weeks and at the end of the study. During this time, the effects of the treatment on liver health will be closely monitored.

Throughout the study, participants will undergo various assessments, including imaging tests like Magnetic Resonance Imaging (MRI), to measure changes in liver fat and other liver-related health markers. The study aims to provide valuable insights into the potential benefits of Pegozafermin for individuals with MASH/NASH and fibrosis, ultimately contributing to better treatment options for this condition.